Abstract
Current evidence shows that thioridazine (THZ) is ready for global clinical evaluation, while some of its derivatives and other efflux pump inhibitors reach the end stage of preclinical evaluation. In this paper, a clinical trial plan is described that investigates the antituberculosis potency, the safety profile and the role of THZ and/or its derivatives in the treatment of TB in humans, both in patients infected with drug sensitive strains as in patients infected with multi or extensive drug resistant strains of Mycobacterium tuberculosis and some of the patents related to thioridazine are also discussed.
Keywords: Global clinical trials, therapy of XDR-TB, thioridazine, TRIAL PLAN, rifampicin, THZ, The OBT Design, Toxicity Profile, Antituberculosis Antibiotics, Compassionate Use
Recent Patents on Anti-Infective Drug Discovery
Title: Global Clinical Trials for the Treatment of TB with Thioridazine
Volume: 6 Issue: 2
Author(s): Martin J. Boeree
Affiliation:
Keywords: Global clinical trials, therapy of XDR-TB, thioridazine, TRIAL PLAN, rifampicin, THZ, The OBT Design, Toxicity Profile, Antituberculosis Antibiotics, Compassionate Use
Abstract: Current evidence shows that thioridazine (THZ) is ready for global clinical evaluation, while some of its derivatives and other efflux pump inhibitors reach the end stage of preclinical evaluation. In this paper, a clinical trial plan is described that investigates the antituberculosis potency, the safety profile and the role of THZ and/or its derivatives in the treatment of TB in humans, both in patients infected with drug sensitive strains as in patients infected with multi or extensive drug resistant strains of Mycobacterium tuberculosis and some of the patents related to thioridazine are also discussed.
Export Options
About this article
Cite this article as:
J. Boeree Martin, Global Clinical Trials for the Treatment of TB with Thioridazine, Recent Patents on Anti-Infective Drug Discovery 2011; 6 (2) . https://dx.doi.org/10.2174/157489111796064533
DOI https://dx.doi.org/10.2174/157489111796064533 |
Print ISSN 1574-891X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4071 |
Related Articles
-
Targeting Bacterial Antioxidant Systems for Antibiotics Development
Current Medicinal Chemistry Exploring Targets of Cell Wall Protein Synthesis and Overexpression Mediated Drug Resistance for the Discovery of Potential M. tb Inhibitors
Current Topics in Medicinal Chemistry Novel Small-Molecule Inhibitors of Arylamine N-Acetyltransferases: Drug Discovery by High Throughput Screening
Combinatorial Chemistry & High Throughput Screening Drug Resistance of Antitubercular Agents at the Genetic Level in Mycobacterium Species: A Road Map to Drug Development for Counteracting the Resistance
Mini-Reviews in Organic Chemistry Why Antidiabetic Vanadium Complexes are Not in the Pipeline of “Big Pharma” Drug Research? A Critical Review
Current Medicinal Chemistry Th17 and Treg Cells, Two New Lymphocyte Subpopulations with a Key Role in the Immune Response Against Infection
Infectious Disorders - Drug Targets Psychosocial Stress, Emotions and Cytokine-Related Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Meet Our Editorial Board Member
Current Medicinal Chemistry Synthetic and Biological Aspects of Thiadiazoles and their Condensed Derivatives: An Overview
Current Topics in Medicinal Chemistry Pharmacogenomic Research in South Africa: Lessons Learned and Future Opportunities in the Rainbow Nation
Current Pharmacogenomics and Personalized Medicine Recent Advances in the Synthesis of Biologically Active Cinnoline, Phthalazine and Quinoxaline Derivatives
Current Organic Chemistry From the Deepest Sea Shelf to the Uppermost Kitchen Cabinet Shelf: The Quest for Novel TNF-α Inhibitors
Current Topics in Medicinal Chemistry General Aspects of Two-Component Regulatory Circuits in Bacteria: Domains, Signals and Roles
Current Protein & Peptide Science Micronutrient Biofortification in Rice through New Breeding Techniques (NBTs): Bangladesh Perspective
Current Nutraceuticals Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology Nitroimidazoles, Quinolones and Oxazolidinones as Fluorine Bearing Antitubercular Clinical Candidates
Mini-Reviews in Medicinal Chemistry Microwave Assisted Preparation of New Dicoumarinyl Pyrazoline Derivatives as Antimicrobials
Current Microwave Chemistry Advancement in Nanoparticle-based Biosensors for Point-of-care <i>In vitro</i> Diagnostics
Current Topics in Medicinal Chemistry Real-time Polymerase Chain Reaction for Mycobacterium tuberculosis Meningitis is More Sensitive in Patients with HIV Co-Infection
Current HIV Research Structural Analysis of Farnesyl Pyrophosphate Synthase from Parasitic Protozoa, a Potential Chemotherapeutic Target
Infectious Disorders - Drug Targets